» Articles » PMID: 36735180

The Therapeutic Potential of Antioxidants in Chemotherapy-Induced Peripheral Neuropathy: Evidence from Preclinical and Clinical Studies

Overview
Specialty Neurology
Date 2023 Feb 3
PMID 36735180
Authors
Affiliations
Soon will be listed here.
Abstract

As cancer therapies advance and patient survival improves, there has been growing concern about the long-term adverse effects that patients may experience following treatment, and concerns have been raised about such persistent, progressive, and often irreversible adverse effects. Chemotherapy is a potentially life-extending treatment, and chemotherapy-induced peripheral neuropathy (CIPN) is one of its most common long-term toxicities. At present, strategies for the prevention and treatment of CIPN are still an open problem faced by medicine, and there has been a large amount of previous evidence that oxidative damage is involved in the process of CIPN. In this review, we focus on the lines of defense involving antioxidants that exert the effect of inhibiting CIPN. We also provide an update on the targets and clinical prospects of different antioxidants (melatonin, N-acetylcysteine, vitamins, α-lipoic acid, mineral elements, phytochemicals, nutritional antioxidants, cytoprotectants and synthetic compounds) in the treatment of CIPN with the help of preclinical and clinical studies, emphasizing the great potential of antioxidants as adjuvant strategies to mitigate CIPN.

Citing Articles

The mechanism of Taohong Siwu decoction in treating chemotherapy-induced peripheral neuropathy: a network pharmacology and molecular docking study.

Zhou M, Liu L, Tan Y, Huang R, Yang Z Transl Cancer Res. 2024; 13(7):3842-3853.

PMID: 39145055 PMC: 11319946. DOI: 10.21037/tcr-24-1019.


Molecular and Cellular Involvement in CIPN.

Kacem H, Cimini A, dAngelo M, Castelli V Biomedicines. 2024; 12(4).

PMID: 38672107 PMC: 11048589. DOI: 10.3390/biomedicines12040751.


Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates.

Fu Z, Gao C, Wu T, Wang L, Li S, Zhang Y iScience. 2023; 26(10):107778.

PMID: 37727735 PMC: 10505985. DOI: 10.1016/j.isci.2023.107778.

References
1.
Hilpert F, Stahle A, Tome O, Burges A, Rossner D, Spathe K . Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische.... Support Care Cancer. 2005; 13(10):797-805. DOI: 10.1007/s00520-005-0782-y. View

2.
Kaplan D, Matsumoto K, Lucarelli E, Thiele C . Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. Eukaryotic Signal Transduction Group. Neuron. 1993; 11(2):321-31. DOI: 10.1016/0896-6273(93)90187-v. View

3.
Li J, Xu L, Deng X, Jiang C, Pan C, Chen L . N-acetyl-cysteine attenuates neuropathic pain by suppressing matrix metalloproteinases. Pain. 2016; 157(8):1711-1723. DOI: 10.1097/j.pain.0000000000000575. View

4.
Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

5.
Sainz R, Mayo J, Rodriguez C, Tan D, Lopez-Burillo S, Reiter R . Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci. 2003; 60(7):1407-26. PMC: 11138606. DOI: 10.1007/s00018-003-2319-1. View